Physicians' Academy for Cardiovascular Education

Lipids

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Elevated Lp(a) levels associated with increased risk of MACE when hsCRP ≥2 mg/L

Literature - July 27, 2020 - Puri R et al., - JAMA Cardiol. 2020.

Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.

Higher frequency of coronary atherosclerotic plaques in patients with genetically confirmed FH

Literature - July 7, 2020 - Pang J et al., - Atherosclerosis. 2020.

Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD
In this video internist Kees Hovingh discusses why screening for FH is important and tools used for its diagnosis.

In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.

Incorporation of genetic testing increases rates of diagnosis for FH

Literature - June 29, 2020 - Brown EE et al., - J Clin Lipidol. 2020.

This study showed that incorporation of genetic testing results in increased numbers of patients diagnosed with definite FH, compared to classification based solely on clinical criteria.

Phase 2 dose-finding study with PCSK9i in children and adolescents with HeFH

Literature - June 18, 2020 - Daniels S et al., - J Clin Lipidol. 2020.

This phase 2 study with alirocumab decreased LDL-c levels and was generally well tolerated in pediatric HeFH patients. Two dosing regimens were selected for further investigation in a phase 3 trial.

Statin therapy effective and safe in children and adolescents with FH

Literature - June 15, 2020 - Anagnostis P et al., - Endocrine 2020.

Statins lowered total cholesterol, LDL-c, triglycerides and apo-B levels and increased HDL-c levels in children and adolescents with FH, as shown in this systematic review and meta-analysis.

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

Triglyceride-rich lipoprotein cholesterol and small-dense LDL-c differently associated with future CV events

Literature - May 12, 2020 - Duran EK et al., - J Am Coll Cardiol. 2020.

Elevated TRL-c levels were associated with increased risk of MI and PAD in women, whereas high sdLDL-c levels were associated with increased risk of MI alone, as shown in a case-cohort study.

Statin reduces total vascular events after stroke or TIA

Literature - May 6, 2020 - Szarek M, et al. - J Am Coll Cardiol. 2020

Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.

Sugar-sweetened beverage consumption associated with adverse changes in HDL-c and triglycerides

Literature - Mar. 5, 2020 - Haslam DE et al., - J Am Heart Assoc. 2020.

High intake of sugar-sweetened beverages was associated with adverse changes in HDL-c and triglyceride, along with higher incidence of dyslipidemias related to low HDL-c and high triglyceride.

PCSK9 inhibitor reduces atherogenic lipids in T2DM patients with mixed dyslipidemia

Literature - Feb. 27, 2020 - Colhoun HM, et al. - Cardiovasc Diabetol 2020

This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD
Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.